![16 9 size People working in a lab](/sites/default/files/hk/en/2022-08/16%209%20size%20People%20working%20in%20a%20lab_0.jpg)
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
![CHMP_website_teaser_card_16_](/sites/default/files/hk/en/2022-06/CHMP_website_teaser_card_16_9.jpg)
June 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
![COVID-19研究中的治疗停止 COVID-19研究中的治疗停止](/sites/default/files/hk/en/2022-06/press-release-holding-image01.jpg)
June 23, 2022
Stop of treatment in COVID-19 study
![T cell](/sites/default/files/hk/en/2022-07/T-cell%201440_810.jpeg)
June 14, 2022
Option to Acquire Trutino Biosciences
![humbnail](/sites/default/files/hk/en/2022-07/thumbnail%281%29.jpg)
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
![BI_PF_ATS_Press-Release_Social BI_PF_ATS_Press-Release_Social](/sites/default/files/hk/en/2022-07/786212706-002_BI_PF_ATS_Press-Release_Social_1920x1080_CC03_image-only_0.jpg)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![TwistPak TwistPak](/sites/default/files/hk/en/2022-07/TwistPak%20hero%20image.jpg)
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
![AI machine deep learning](/sites/default/files/hk/en/2022-08/AI%20machine%20deep%20learning.jpg)
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
![048_© 2020, Peter Ginter - final adjustments at the “pipe crossover” resized](/sites/default/files/hk/en/2022-08/048_%C2%A9%202020%2C%20Peter%20Ginter%20-%20final%20adjustments%20at%20the%20%E2%80%9Cpipe%20crossover%E2%80%9D%20resized.jpeg)
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
![新的spesolimab数据显示GPP复发显著改善](/sites/default/files/hk/en/2022-06/AAD%20press%20release%20supporting%20image_resized.png)
March 28, 2022
New spesolimab data show significant improvement in GPP flares
![AAD press release](/sites/default/files/hk/en/2022-08/AAD%20press%20release%20supporting%20image_resized.jpeg)
March 28, 2022
New spesolimab data show clinically significant improvement in GPP flares
![勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究 勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究](/sites/default/files/hk/en/2022-06/_15A3705_0.jpg)
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
![220316_EMPA-KIDNEY_Early-Stop](/sites/default/files/hk/en/2022-08/220316_EMPA-KIDNEY_Early-Stop_0.jpg)
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
![EMA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/EMA_website_teaser_card_16_9.jpg)
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
![EMPULSE_Image_2_Doctor_Patient](/sites/default/files/hk/en/2022-06/EMPULSE_Image_2_Doctor_Patient.jpg)
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
![FDA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/FDA_website_teaser_card_16_9.jpg)
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
![786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01 786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01](/sites/default/files/hk/en/2022-06/786212575-009_BI_IPF_FDA%20Asset_1440X810_CC01-01.jpg)
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
![test test](/sites/default/files/hk/en/2022-02/2-5.jpg)
February 16, 2022
Boehringer Ingelheim opens Health Management Centre in China
![black cow black cow](/sites/default/files/hk/en/2022-06/black%20cow%202.jpg)
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
![Mediapool_TopEmployer2022](/sites/default/files/hk/en/2022-08/Mediapool_TopEmployer2022%20%281%29.jpg)
January 20, 2022
Award: Boehringer Ingelheim is Global Top Employer 2022
![Immuno Immuno](/sites/default/files/hk/en/2022-09/400x400smallformat_Immuno.jpg)
January 18, 2022
Collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/400x400smallformat_Digital1.jpg)
January 03, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
![EMA验证了spesolimab在GPP中的上市许可申请](/sites/default/files/hk/en/2022-06/press-release-holding-image03_1.jpg)
December 29, 2021
EMA validates spesolimab marketing authorization application in GPP
![Spesolimab II期数据](/sites/default/files/hk/en/2022-06/Supporting%20press%20release%20image.png)
December 23, 2021
Spesolimab Phase II data
![美国FDA授予spesolimab在GPP中的优先审评](/sites/default/files/hk/en/2022-06/211213%20FDA%20Press%20Release%20Image_1440x810_72dpi_cc01.jpg)
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/press-release-holding-image01_0.jpg)
December 10, 2021
Boehringer Ingelheim Launches University of Medicine Excellence
![Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements](/sites/default/files/hk/en/2022-06/BISE_Bungoma_County%5B1%5D.jpg)
November 11, 2021
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
![共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法 共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法](/sites/default/files/hk/en/2022-06/MMHT_visual.jpg)
November 11, 2021
Making More Health Together 2021: Creating sustainable health solutions for 50 million people in vulnerable communities
![防腐肾亚组分析 press-release-holding-image02_1.jpg](/sites/default/files/hk/en/2022-06/press-release-holding-image02_1.jpg)
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人 勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人](/sites/default/files/hk/en/2022-06/More%2520Potential_Picture%2520for%2520Tweet%5B1%5D.jpg)
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
![Kachelbild SOL](/sites/default/files/hk/en/2022-06/Kachelbild%20SOL.jpeg)
October 27, 2021
科学与创新
![与伦敦大学国王学院的精神卫生合作](/sites/default/files/hk/en/2022-07/AdobeStock_KCL.jpeg)
October 27, 2021
Mental health collaboration with King’s College London
![尿素循环障碍治疗发展伙伴关系](/sites/default/files/hk/en/2022-07/cardpic.png)
October 26, 2021